Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NITROFURANTOIN MONO/MICRO CRYSTALS

All products: general benefit

Other products in the same Health Canada class (J01X, J01XE) — coverage varies; not interchangeable

  • Nitrofurantoin (Macrodantin): general benefit, Not a benefit
  • Fosfomycin tromethamine (Monurol): general benefit

PMS-Nitrofurantoin BID · DIN 02455676 · 100mg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Nitrofurantoin BID · DIN 02455676 Manufacturer: Pharmascience Inc.; listing date 2018-07-31 Health Canada: Marketed since 2021-08-11 · brand PMS-NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3067 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248 · Verify on the e-Formulary ↗ (DIN 02455676)

Source record
DIN 02455676: PMS-Nitrofurantoin BID Raw flags: sec3=Y Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id PMS Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.3067; ministry $0.3067 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455676 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248
Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067 Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067 MacroBID · DIN 02063662 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:36 Urinary Anti-Infectives) and how they are covered

Matched class: 08:36 Urinary Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FOSFOMYCIN TROMETHAMINE Some products covered without a code (check the product listing): NITROFURANTOIN 08:36 Urinary Anti-Infectives

NITROFURANTOIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 50mg, 100mg · Cap, Tab

FOSFOMYCIN TROMETHAMINE

· 2 products · General benefit · strengths: · Sachet-3g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:36
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-NITROFURANTOIN BID is indicated for the treatment of acute uncomplicated urinary tract infections, e.g., cystitis, when due to susceptible strains of Escherichia coli, and Staphylococcus saprophyticus. pms-NITROFURANTOIN BID is not indicated for the treatment of associated renal cortical or perinephric abscesses. pms-NITROFURANTOIN BID is not indicated for therapy of any systemic infections or for use in prostatitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of pms-NITROFURANTOIN BID and other antibacterial drugs, pms-NITROFURANTOIN BID pms-NITROFURANTOIN BID Product Monograph Page 2 of 21 should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. https://pdf.hres.ca/dpd_pm/00057835.PDF PM date: August 26, 2020 Source product: PMS-NITROFURANTOIN BID; DIN 02455676; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.